Literature DB >> 27552620

Time in Therapeutic Range in Warfarin-Treated Patients: Is Very Good Good Enough?

Rod Passman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27552620     DOI： 10.1001/jama.2016.10402

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis.

Authors:  Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Kevin Troy; Thomas Schiano; John Mascarenhas
Journal:  Blood Adv       Date:  2020-02-25

2.  Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.

Authors:  Shadi Yaghi; Eva Mistry; Ava L Liberman; James Giles; Syed Daniyal Asad; Angela Liu; Muhammad Nagy; Ashutosh Kaushal; Idrees Azher; Brian Mac Grory; Hiba Fakhri; Kiersten Brown Espaillat; Hemanth Pasupuleti; Heather Martin; Jose Tan; Manivannan Veerasamy; Charles Esenwa; Natalie Cheng; Khadean Moncrieffe; Iman Moeini-Naghani; Mithilesh Siddu; Erica Scher; Tushar Trivedi; Aaron Lord; Karen Furie; Salah Keyrouz; Amre Nouh; Christopher R Leon Guerrero; Adam de Havenon; Muhib Khan; Nils Henninger
Journal:  Stroke       Date:  2020-08-06       Impact factor: 7.914

3.  Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.

Authors:  Nicholas L Syn; Andrea Li-Ann Wong; Soo-Chin Lee; Hock-Luen Teoh; James Wei Luen Yip; Raymond Cs Seet; Wee Tiong Yeo; William Kristanto; Ping-Chong Bee; L M Poon; Patrick Marban; Tuck Seng Wu; Michael D Winther; Liam R Brunham; Richie Soong; Bee-Choo Tai; Boon-Cher Goh
Journal:  BMC Med       Date:  2018-07-10       Impact factor: 8.775

4.  Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.

Authors:  Zipporah Kamuren; Gabriel Kigen; Alfred Keter; Alice Maritim
Journal:  BMC Health Serv Res       Date:  2018-09-19       Impact factor: 2.655
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.